Table 1 Clinical characteristics of the 34 pre-operative plasma EOC patients and 21 healthy controls in discovery set and validation set
Data set | No. | Age (Year) | Pathological diagnosis | Stage | Grade | Pre-operative CA125(U/mL) | BRCA mutation status | Concurrent cancer |
|---|---|---|---|---|---|---|---|---|
Discovery set | EOC1 | 65 | EOC | IVB | NAa | NA | BRCA- | – |
EOC2 | 43 | EOC | IIIC | NA | NA | BRCA- | – | |
EOC3 | 67 | EOC | IIIC | NA | NA | BRCA+ | – | |
EOC4 | 45 | EOC | IIIC | NA | NA | BRCA- | – | |
EOC5 | 57 | EOC | IVB | NA | NA | BRCA+ | – | |
EOC6 | 55 | EOC | IIIC | NA | NA | BRCA+ | Breast cancer | |
Ctrl1 | 52 | Healthy control | – | – | – | NA | – | |
Ctrl2 | 62 | Healthy control | – | – | – | NA | – | |
Ctrl3 | 48 | Healthy control | – | – | – | NA | – | |
Ctrl4 | 50 | Healthy control | – | – | – | NA | – | |
Validation set | C1 | 56 | EOC | IIIC | 1 | 49.1 | BRCA- | – |
C2 | 44 | EOC | IIIC | 3 | 6354 | BRCA- | – | |
C3 | 53 | EOC | IIIC2 | 3 | 1648 | BRCA- | – | |
C4 | 56 | EOC | IIIC | 1 | 474.8 | BRCA- | – | |
C5 | 70 | EOC | IIC | 2 | 2221 | BRCA- | – | |
C6 | 60 | EOC | IIIC | 3 | 977.4 | BRCA+ | – | |
C7 | 51 | EOC | IIIC | 3 | 93 | BRCA- | – | |
C8 | 54 | EOC | NA | NA | 12.9 | NA | – | |
C9 | 51 | EOC | IIIC | 3 | 1359 | BRCA+ | – | |
C10 | 35 | EOC | IIIA1 | NA | 253.9 | BRCA- | – | |
C11 | 61 | EOC | IV | 3 | 880.4 | BRCA+ | – | |
C12 | 49 | EOC | IIA | 3 | 107 | BRCA+ | – | |
C13 | 50 | EOC | IIIB | 3 | 690.7 | NA | – | |
C14 | 66 | EOC | IIIC | NA | 19.1 | NA | – | |
C15 | 43 | EOC | IIIC | 3 | 31.7 | NA | – | |
C16 | 52 | EOC | IIIC | NA | 63.9 | NA | – | |
C17 | 61 | EOC | IIIC | NA | 20,388.1 | NA | – | |
C18 | 49 | EOC | IIIC | NA | 923.9 | NA | – | |
C19 | 74 | EOC | IV | NA | 1311.1 | BRCA+ | – | |
C20 | 51 | EOC | IV | 3 | 876.8 | NA | – | |
C21 | 61 | EOC | IIIC | 3 | 278 | BRCA+ | – | |
C22 | 56 | EOC | IIIC | 3 | 3862 | BRCA- | – | |
C23 | 56 | EOC | IC | 3 | 191.2 | BRCA- | – | |
C24 | 46 | EOC | IC | 3 | 57.9 | NA | – | |
C25 | 65 | EOC | IIC | 3 | 128.4 | BRCA+ | – | |
C26 | 64 | EOC | IC | 2 | 145.5 | BRCA+ | – | |
C27 | 64 | EOC | IV | NA | 876.8 | BRCA- | – | |
C28 | 74 | EOC | IIIC | NA | 10.6 | NA | – | |
H1 | 42 | Healthy control | – | – | – | – | – | |
H2 | 59 | Healthy control | – | – | – | – | – | |
H3 | 46 | Healthy control | – | – | – | – | – | |
H4 | 53 | Healthy control | – | – | – | – | – | |
H5 | 54 | Healthy control | – | – | – | – | – | |
H6 | 55 | Healthy control | – | – | – | – | – | |
H7 | 41 | Healthy control | – | – | – | – | – | |
H8 | 53 | Healthy control | – | – | – | – | – | |
H9 | 45 | Healthy control | – | – | – | – | – | |
H10 | 56 | Healthy control | – | – | – | – | – | |
H11 | 37 | Healthy control | – | – | – | – | – | |
H12 | 60 | Healthy control | – | – | – | – | – | |
H13 | 58 | Healthy control | – | – | – | – | – | |
H15 | 34 | Healthy control | – | – | – | – | – | |
H16 | 54 | Healthy control | – | – | – | – | – | |
H18 | 55 | Healthy control | – | – | – | – | – | |
H20 | 43 | Healthy control | – | – | – | – | – |